Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer
ABSTRACT Osimertinib is the only third‐generation EGFR tyrosine kinase inhibitor clinically approved for first‐line treatment of advanced NSCLC patients harboring EGFR mutations. However, drug resistance severely hinders its clinical efficacy. Acquired MET amplification is an important mechanism cau...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | MedComm – Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mog2.70019 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|